|
![]() |
|||
|
||||
OverviewFull Product DetailsAuthor: Kenneth D. Tew (Professor and Chairman, Department of Cell and Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA) , Paul Fisher , Kenneth D. Tew (Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA) , Kenneth D. Tew (Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc Volume: 118 Weight: 0.780kg ISBN: 9780124071735ISBN 10: 0124071732 Pages: 416 Publication Date: 31 July 2013 Audience: Professional and scholarly , Professional and scholarly , Professional & Vocational , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand ![]() We will order this item for you from a manufactured on demand supplier. Table of Contents1. Role of Oxidative Stress and Microenvironment in Breast Cancer Development and Progression 2. Bioengineering Strategies for Cancer Targeting 3. Advances in Understanding the Coupling of DNA Base Modifying Base Enzymes to Processes Involving Base Excision Repair 4. Recent Advances in the Treament of Prostrate Cancer Stemming from Improvements in the Biology of the Disease 5. Autophagy: Cancer's Friend or FoeReviewsPraise for the Serial: This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences. --AMERICAN SCIENTIST Excellent, highly informative, in-depth reviews...expertly written, up-to-date, and well-referenced. --JOURNAL OF MEDICINAL CHEMISTRY This is a series that has a long tradition of excellence in the field of cancer biology. --DOODY'S PUBLISHING REVIEW "Praise for the Serial: ""This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences.""--AMERICAN SCIENTIST ""Excellent, highly informative, in-depth reviews...expertly written, up-to-date, and well-referenced.""--JOURNAL OF MEDICINAL CHEMISTRY ""This is a series that has a long tradition of excellence in the field of cancer biology.""--DOODY'S PUBLISHING REVIEW" Praise for the Serial This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences. --American Scientist Excellent, highly informative, in-depth reviews.expertly written, up-to-date, and well-referenced. --Journal of Medicinal Chemistry This is a series that has a long tradition of excellence in the field of cancer biology. --Doody's Publishing Reviews Praise for the Serial: ""This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences.""--AMERICAN SCIENTIST ""Excellent, highly informative, in-depth reviews...expertly written, up-to-date, and well-referenced.""--JOURNAL OF MEDICINAL CHEMISTRY ""This is a series that has a long tradition of excellence in the field of cancer biology.""--DOODY'S PUBLISHING REVIEW Author InformationProfessor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USAThe Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation. Tab Content 6Author Website:Countries AvailableAll regions |